AKBA
Akebia Therapeutics
Phase 2
Estimated
Praliciguat
Focal Segmental Glomerulosclerosis
T-minus 268 days
~ Jun 30, 2027
ClinicalTrials.gov
verified 3mo ago
Countdown card →